SYNTHESIS OF (8Z,14Z)-13,13-DIMETHYLEICOSA-8,14-DIEN-11-YNOIC ACID AS AN INHIBITOR OF PROSTAGLANDIN CYCLOOXYGENASE

Chin-Lung Yeh and Marcia Dawson*

Department of Bio-Organic Chemistry, Stanford Research Institute

Menlo Park, California 94025

and

Martin E. Hemler and William E.M. Lands

Department of Biological Chemistry, University of Michigan Medical School


Ann Arbor, Michigan 48104


(Received in USA 18 July 1977; received in UK for publication 13 October 1977)


As a continuation of our program to prepare (8Z,11Z,14Z)-8,11,14- eicosatrienoic acid analogs with potential prostaglandin synthetase inhibitory activity, (8Z,14Z)-13,13-dimethyleicosa-8,14-dien-11-ynoic acid $(\underline{11})$ was synthesized. This analog, which was envisioned as an inhibitor of prostaglandin cyclooxygenase, was readily prepared in a 3 + 10 step convergent synthesis using the two intermediates 1-bromo-9-chloro-2-nonyne $(\underline{4})$ and (4Z)-3,3-dimethyldec-4-en-1-yne $(\underline{9})$.


Displacement 2 of iodide from 1-chloro-6-iodohexane 3 by the lithium salt of tetrahydro-2-(prop-2'-ynyloxy)pyran 4 (2) (THF/NH $_3$, 8 hr) afforded 3 (77% yield). 5 Acid-catalyzed removal of the tetrahydropyranyl protecting group (\underline{p} -TsOH, MeOH, 5 hr reflux, 88% yield) and PBr $_3$ treatment 6 (Et $_2$ O, pyridine, 0°, 30 min PBr $_3$ addition, 3-hr reflux, 65% yield) gave the intermediate 1-bromo-9-chloro-2-nonyne ($\underline{4}$).

2,2-Dimethyl-1,3-propanediol was converted to the hydroxy monobenzyl ether 6 (NaH, DMF, ϕ CH₂Cl, amb temp, 14 hr, 7 52% yield), which was oxidized with Collins reagent 8 to the aldehyde (bp 76-78°/0.5 mm, 50% yield). Immediate treatment with hexyltriphenyl phosphorane (C₆H₁₃ ϕ ₃Br, 9 NaH, DMSO, 24 hr, room









temp, 70% yield) afforded the 2-olefin 7, as the major product: bp 141-142°/ 0.9 mm; ir (film) 2930, 2860, 1450, 1100, 760, 740, 700 cm $^{-1}$; nmr (CDCl₂) δ 2.0 (m, $J_{1,3} = -1.7$, $J_{1,4} = -1.7$, $J_{2,3} = 7.5$, $J_{2,4} = 7.5$, $J_{3,4} = 14$, $\tilde{2}$, $H(1)C=CH(2)-C\underline{H}(3)\underline{H}(4)), 3.26 \text{ (s, 2, } C\underline{H}_2OC\underline{H}_2C_6\underline{H}_5), 4.54 \text{ (s, 2, } C\underline{H}_2C_6\underline{H}_5), 5.47$ (m, $J_{1,2} = 12$, $J_{2,3} = 7.5$, $J_{2,4} = 7.5$, 1, H(1)C=CH(2)-CH(3)H(4)), 5.52 (m, $J_{1,2} = 12$, $J_{1,3} = -1.7$, $J_{1,4} = -1.7$, 1, H(1)C=CH(2)-CH(3)H(4)), 7.30 (s, 5, C_6H_5). Debenzylation (Na, Et_2O/NH_3 , 40 min) afforded the alcohol 8, (80%) yield) which was oxidized with Collins reagent⁸ to the aldehyde. Wittig reaction 10 [(chloromethyl)-triphenylphosphonium chloride, (<u>n</u>-BuLi, THF-Et₂O, -78° 3 hr, 65% yield] followed by dehydrochlorination (n-BuLi, Et,O-hexane, 0° addition, amb. temp. 2.5 hr, 80% yield) afforded the enyne 9: ir (film) 3340 (HC=C), 2100 (C=C), 1650 (C=C), 1460, 1240, 730 cm⁻¹; nmr (CDCl₂) δ 1.40 (s, 6, $C(CH_3)_2$), 2.17 (s, 1, $HC \equiv C$), 5.36 (m, 2, $HC \equiv CH$). Freshly distilled (100°/15 mm) enyne 9, after conversion to the Grignard reagent (EtMgBr, Et₂0)¹¹ was coupled to the freshly distilled propargylic bromide 4 (Cu₂Cl₂, Et₂O-THF, 2.5 hr) to afford a 51% yield of (13%)-1-chloro-12,12-dimethylnonadeca-7,10-diyn-13-ene: ir (CHCl₃) 2200 (CEC), 1310 (CECCH₂CEC); nmr (CDCl₃) δ 1.30 (s, 6, C(CH₃)₂), 3.10 (t, J - 2, 2, $C = CCH_2C = C$), 3.52 (t, J - 6, 2, CH_2C1), 5.28 (m, 2, HC = CH).

Selective hydrogenation 11 of the Grignard coupling product (Lindlar catalyst, 12 80 min; silica gel chromatography with hexane) reduced the less hindered acetylenic bond to give (72,132)-1-chloro-12,12-dimethylnonadeca-7,13-dien-10-yne $(\underline{10})$: 78% yield; ir (film) 1650 (C=C), 1460, 1290, 730 cm⁻¹; nmr (CDCl₃) & 1.22 (s, 6, C(CH₃)₂), 2.90 (d, J = 4.5, 2, C=CCH₂C=C), 3.50 (t, J = 6, 2, CH₂Cl), 5.05-5.6 (2 m, 4, HC=CH). Grignard formation 11 of the chlorodienyne $\underline{10}$, followed by carbonation, produced after chromatography (silica gel, 10% EtOAc in hexane) a 34% yield of the target compound $\underline{11}$. ir (film) 2670, 1710, 1650, 1430, 1370, 930 cm⁻¹; nmr (CDCl₃) & 1.28 (s, 6, (CH₃)₂), 2.34 (m, 2, CH₂CO₂), 2.90 (d, J = 6, 2, C=CCH₂C=C), 5.2-5.8 (m, 4, HC=CH), 10.0 (s, 1, CO₂H); n_{D}^{270} 1.4772; VPC (3% OV-1, 1/8" x 6' column, 270°) of methyl ester, one peak (rt = 4.3 min).

Biochemical studies with this 13,13-dimethyl analog showed that the absence of the L-hydrogen at C-13, which is normally lost during bioconversion of eicosatrienoic acid by either purified prostaglandin cyclooxygenase or soybean lipoxygenase, prevented oxidation by either enzyme but still allowed normal competitive binding ($K_{\rm I}$ ~8 μM) to the active site. This $K_{\rm I}$ value is comparable to those reported for other long-chain poly-unsaturated acids (2-15 μM). 13 The reversible, competitive nature of the inhibition by this analog appears to be due to simple acyl chain adsorption to the active site; no irreversible inactivation occurred as seen for some other substrate analogs. 14

Acknowledgements

Support of the synthetic portion of this work by the National Institutes of Child Health and Human Development, Contract No. NO1-HD-4-2843, is gratefully acknowledged. We also wish to express our gratitude to Mr. Mark Vasser for skillful technical assistance.

References and Footnotes

- 1a. For earlier papers in this series see M. Dawson and M. Vasser, <u>J. Org. Chem.</u>, in press, and M. Dawson, M. Reid, M. Hemler, and W.E.M. Lands, J. Med. Chem., in press.
- b. The syntheses of other methyl-substituted eicosatrienoic acids have been reported. For example, R. van der Linde, L. van der Wolf, H.J.J. Pabon, and D. A. van Dorp, <u>Rec. trav. chim.</u>, <u>94</u>, 257 (1975); and U. H. Do and H. Sprecher, Arch. Biochem. Biophys., <u>171</u>, 597 (1975).
- 2. D. E. Ames, A. N. Covell, and T. G. Goodburn, <u>J. Chem. Soc.</u>, 5889 (1963).
- 3. R. A. Raphael and F. Sondheimer, J. Chem. Soc., 2100 (1950).
- 4. D. N. Robertson, J. Org. Chem., 25, 932 (1960).
- 5. New compounds were submitted to high resolution mass spectral and/or combustion analyses, which were satisfactory.
- 6. W. R. Taylor and F. M. Strong, J. Am. Chem. Soc., 72, 4263 (1950).
- 7. U. E. Diner, F. Sweet, and R. K. Brown, Can. J. Chem., 44, 1591 (1966).
- 8. R. Ratcliffe and R. Rodehorst, J. Org. Chem., 35, 4000 (1970).
- 9. G. Wittig and U. Schoellkopf, Org. Syn., 40, 66 (1960).
- 10. G. Köbrich, H. Trapp, K. Flory, and W. Drischel, <u>Chem. Ber.</u>, <u>99</u>, 689 (1966).
- 11. S. N. Ege, R. Wolovsky, and W. J. Gensler, <u>J. Am. Chem. Soc.</u>, <u>81</u>, 3080 (1961).
- 12. H. Lindlar, Helv. Chim. Acta, 35, 446 (1952).
- 13. W.E.M. Lands, P. R. LeTellier, L. H. Rome, and J. Y. Vanderhock, Adv. in Biosciences, 9, 15 (1973).
- 14. J. Y. Vanderhock and W.E.M. Lands, <u>Biochem. Biophys, Acta</u>, <u>296</u>, 374 (1973).